Here’s a paper done in vivo by the NIH on the effects of dasatanib on senescent cells in adipose tissue. D+Q targets senescent cells in adipose tissue which is where most senescent cells are found. They are also likely the most damaging of all senescent cells.
The study you reference is in vitro and funded by a company with a financial stake. I’ll take an in vivo study by an unbiased entity any day over one with a conflict of interest.
Azithromycin may work well, but there’s only so many senescent cells you can destroy. At one point, it may become overkill.
Because senescent cells can take weeks to months to develop and do not divide, and because even eliminating only 30% of senescent cells can be sufficient to alleviate dysfunction in preclinical studies [3,5,7,9,23,24,28,[32], [33], [34], [35], [36], [37]], D + Q is as effective in mice if administered intermittently, for example every 2 weeks to a month, as continuously, even though D and Q have elimination half-lives of only 4 and 11 h, respectively [38,39]. This is consistent with the point that, since the target of senolytics is senescent cells, these drugs do not need to be continuously present in the circulation in the same way as drugs whose mechanism of action is to occupy a receptor, modulate an enzyme, or act on a particular biochemical pathway, at least in mice. Intermittently administering D + Q effectively circumvents any potential off-target effects due to continuous receptor occupancy or modulation of an enzyme or biochemical pathway.
Here is another paper that talks about azithromycin, dasatanib + quercetin and other senolytics:
https://www.sciencedirect.com/science/article/pii/S2468501120300286
To mix quotes:
There is always more than one way to skin a black cat in a dark room.
Your way may work. My way may work. I hope for the best for all of us.
